Sort   by:  
 Page size 
UnknownClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Not available
S-EPMC6008108 | biostudies-literature
UnknownPhase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Not available
S-EPMC11756386 | biostudies-literature
UnknownEfficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Not available
S-EPMC10844204 | biostudies-literature
UnknownMechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Not available
S-EPMC7146021 | biostudies-literature
UnknownDifferentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Not available
S-EPMC5885269 | biostudies-literature
UnknownA phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Not available
S-EPMC5773400 | biostudies-literature
UnknownHypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.
Not available
S-EPMC10008622 | biostudies-literature
UnknownA phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Not available
S-EPMC6511975 | biostudies-literature
UnknownOral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Not available
S-EPMC11958769 | biostudies-literature
UnknownMolecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Not available
S-EPMC7218420 | biostudies-literature
Sort   by:  
 Page size